YY/T 1465.4-2017Immunogenic evaluation method of medical devices - Part 4: Phagocytosis of mouse peritoneal macrophages on chicken erythrocytes- Ex-vivo method (English PDF)
医疗器械免疫原性评价方法 第4部分:小鼠腹腔巨噬细胞吞噬鸡红细胞试验半体内法
This is a limited preview
Buy now to download the full PDF (24 pages)
Need quotation for your management?
Get a formal quotation for YY/T 1465.4-2017 in 30 minutes.
Issued by
NMPA
Level / Type
Industry · Recommended
Issue date
March 28, 2017
Implementation date
April 1, 2018
Scope
YY/T 1465.4-2017 is the English-translated version of 医疗器械免疫原性评价方法 第4部分:小鼠腹腔巨噬细胞吞噬鸡红细胞试验半体内法.
YY/T 1465.4-2017 is the Chinese pharmaceutical industry standard that gives the ex vivo method for measuring the phagocytosis of chicken erythrocytes by mouse peritoneal macrophages, used to judge how a medical device or material affects that function.
It is the fourth part of the YY/T 1465 series on immunogenic evaluation and sets out the animals and the harvesting of the macrophages, the exposure to the test article, the incubation with the erythrocytes, the staining and the counting, and the calculation of the phagocytic rate and index. Issued on 28 March 2017, it has applied since 1 April 2018.
Found what you need?
Document preview — YY/T 1465.4-2017
National Standard of the People's Republic of China
Issued by: National Medical Products Administration of the People's Republic of China
Contents
- Foreword3
- Introduction4
- 1 Scope5
- 2 Normative references5
- 3 Terms and definitions5
- 4 Test principles6
- 5 Test animal6
- 6 Sample preparation and route of exposure6
- 7 Selection of control sample7
- 8 Test procedures7
- 9 Result calculation9
- 10 Result judgement9
- 11 Reliability inspection9
- 12 Test report10
1 Scope
This Part of YY/T 1465 gives the ex-vivo method for the determination of phagocytosis of mouse peritoneal macrophages on chicken erythrocytes.
This Part applies to the evaluation of the influence of medical devices/materials on phagocytic ability of macrophages.
2 Normative references
The following documents are indispensable for the application of this document.
For the dated references, only the versions with the dates indicated are applicable to this document. For the undated references, the latest version (including all the amendments) are applicable to this document.
GB/T 16886.1 Biological evaluation of medical devices - Part 1. Evaluation and testing within a risk management process (GB/T 16886.1-2011, ISO 10993-1:2009, IDT)
GB/T 16886.2 Biological evaluation of medical devices - Part 2. Animal welfare requirements (GB/T 16886.2-2011, ISO 10993-2:2006, IDT)
GB/T 16886.11 Biological evaluation of medical devices - Part 11. Tests for systemic toxicity (GB/T 16886.11-2011, ISO 10993-6:2006, IDT)
GB/T 16886.12 Biological evaluation of medical devices - Part 12. Sample preparation and reference materials (GB/T 16886.12-2005, ISO 10993- 12.2002, IDT)
GB/T 16886.20 Biological evaluation of medical devices - Part 20. Principles and methods for immunotoxicology testing of medical devices (GB/T 16886.20-2015, ISO/TS 10993-20:2006, IDT)
3 Terms and definitions
with reference to the requirements of acute, subacute, subchronic, and chronic systemic toxicity tests in GB/T 16886.11, and shall be stated in the final test report.
Note. The immunogens in medical devices are mostly macromolecular substances. If sample extracts are prepared, the effectiveness of the selective extraction method shall be explained.
6 Sample preparation and route of exposure
6.2 For degradable medical devices, it shall, according to intended clinical application mode, design the device-animal contact/immune mode. When there is available research literature, the method reported in the existing literature can be used for test design, to compare with the existing data. When there is no animal contact/immune mode which can be referenced, an implantation route similar to the intended clinical application mode may be considered.
6.3 The liquid test substance can be used directly or diluted.
7 Selection of control sample
7.1 Positive control Recommended
positive control substances which can promote phagocytic ability of macrophages include. 100 IU/g gamma interferon (IFN-gamma) or 10 mg/kg phytohemagglutinin A (PHA). Positive control substances capable of inhibiting phagocytic ability of macrophages include. 5 mg/kg dexamethasone or 200 mg/kg cyclophosphamide. Other fully-demonstrated positive control test substances can also be used. The selection and application mode of positive control substances shall be determined according to the intended use of the test samples and the purpose of the test.
7.2 Negative control
The extraction medium (such as normal saline) recommended in GB/T 16886.12 is used and treated in the same way as the test sample.
Note. When there is a known marketed product which has a long-term clinical use history and of which the immunotoxicity level has been considered acceptable and the composition and intended use mode are the same as the test sample, it can also be used as a negative control, but its application requires a full demonstration.
8 Test procedures
8.1 Test grouping
for 30 min. After the incubation, RINSE in normal saline, to remove anchorage-independent cells. After drying, USE 1.1 acetone-methanol solution to fix it for 5 min, and USE 4% (volume fraction) Giemsa-phosphate buffer dye solution to stain for 3 min; FLUSH with running water; and RINSE with distilled water and DRY it.
9 Result calculation
The macrophages are counted under a microscope. Each slide is randomly counted for 200. The phagocytic percentage and the phagocytic index of each animal shall be calculated according to the formulas (1) and (2).
Note 1. If the drop slide is too dark, it can be decolored with 1% HCl. If it is too light, it can be re-dyed.
Note 2. If the fluid drawn out of the peritoneal cavity is bloody exudate, it shall not be used.
10 Result judgement
When the test group and the negative control group show statistically significant difference in the phagocytic percentage and the phagocytic index, it can be considered that the test substance has an impact on the phagocytic function of mouse macrophages. If a gradient-diluted material or its extract is used for the test, and there is dose-effect relationship between the phagocytic percentage and the phagocytic index, it suggests that the phagocytic function of macrophages may be affected.
11 Reliability inspection
11.1 The positive control is to, by using the substance which has been proven to promote or inhibit the phagocytic function of macrophages, confirm the suitability of the test. When it is necessary to verify that the laboratory is capable of performing this test and performing in-lab repeatability and interlaboratory reproducibility evaluations, positive control is recommended for each test.
11.2 For laboratories which frequently perform this test (Frequency is not less than once a month) and have long-term positive control data proving their ability Phagocytic percentage Phagocytic index Number of macrophages which phagocytose chicken erythrocytes Total number of macrophages counted Total number of chicken erythrocytes which are phagocytosed Total number of macrophages counted
......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 24 pages — is available in the English PDF.
Referenced standards
Normative references
- GB/T 16886.1Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
- GB/T 16886.2Biological evaluation of medical devices - Part 2: Animal welfare requirements
- GB/T 16886.11Biological evaluation of medical devices - Part 11: Tests for systemic toxicity
- GB/T 16886.12Biological evaluation of medical devices - Part 12: Sample preparation and reference materials
- GB/T 16886.20Biological evaluation of medical devices-Part 20:Principles and methods for immunotoxicology testing of medical devices
Similar standards
How to Download YY/T 1465.4-2017
- 1
Add to cart
Click "Download PDF" on this page and choose "Buy this standard". You can add more standards before checkout.
- 2
Checkout
Enter your email and billing details. Payment is processed securely by Stripe (cards or bank transfer). Prefer bank details? Request a quotation (min. order $300).
- 3
Instant delivery (0–9 sec)
Delivery is automatic: within seconds of payment you'll receive an email with a secure download link. The link stays valid for 72 hours.
- 4
Invoice included
A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.
Related Standards
GB/T 16886.1-2022 — Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
GB/T 16886.11-2021 — Biological evaluation of medical devices - Part 11: Tests for systemic toxicity
GB/T 16886.12-2023 — Biological evaluation of medical devices - Part 12: Sample preparation and reference materials
Secure payment via Stripe
Payments accepted
YY/T 1465.4-2017
$125.00